1 / 6

Switch studies in virologically suppressed patients

Switch studies in virologically suppressed patients. Switch to TDF/FTC/EFV AI266-073 Switch to FTC + ddI + EFV ALIZE Switch to ATV/r-containing regimen ATAZIP Switch to ATV ± r-containing regimen SWAN SLOAT Switch to ATV-containing regimen ARIES INDUMA Switch to ATV/r monotherapy

chance
Télécharger la présentation

Switch studies in virologically suppressed patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Switch studies in virologically suppressed patients Switch to TDF/FTC/EFV AI266-073 Switch to FTC + ddI + EFV ALIZE Switch to ATV/r-containing regimen ATAZIP Switch to ATV±r-containing regimen SWAN SLOAT Switch to ATV-containing regimen ARIES INDUMA Switch to ATV/r monotherapy ATARITMO Swedish Study ACTG A5201 OREY Synopsis • Switch to LPV/r monotherapy • Pilot LPV/r • M03-613 • American Study • KalMo • OK • OK04 • KALESOLO • MOST • HIV-NAT 077 • Switch to DRV/r monotherapy • MONOI • MONET • Switch to RAL-containing regimen • Canadian Study • CHEER • Montreal Study • EASIER • SWITCHMRK • SPIRAL

  2. EASIER Study: Switch ENF to RAL • Design Randomisation 1 : 1 Open-label W24 193 HIV+ adults History of triple class (NRTI, NNRTI, PI) failure or intolerance HIV-1 RNA < 400 c/mL > 3 monthson an ENF-based regimen Integrase inhibitor-naïve N = 85 N = 85 • Objective • Non inferiority in the proportion of patients with virologic failure at W24(Intent-to-treat analysis) ; upper limit of the 95% CI for the difference =10%, 80% power • Virologic failure : confirmed HIV-1 RNA ≥ 400 c/mL, or a singleHIV-1 RNA ≥ 400 c/mL followed by treatment modification or last HIV-1 RNA ≥ 400 c/mL without confirmation De Castro N, CID 2009;49:1259-67 EASIER

  3. EASIER Study: Switch ENF to RAL Baseline characteristics and patient disposition * TPV/r in 34% vs 44% and DRV/r in 40% vs 36%, in ENF vs RAL groups, respectively De Castro N, CID 2009;49:1259-67 EASIER

  4. EASIER Study: Switch ENF to RAL HIV-1 RNA < 50 c/mL % ENF RAL 100 89 88 80 60 40 20 1.2 1.2 1.2 0 0 On-treatment analysis ITT analysis ITT analysis 95% CI for the difference= -6.7 ; 6.8 95% CI for the difference= -5.6 ; 8.1 Outcome at week 24 Virologic failure Other endpoints • Median CD4 increase • ENF: +15/mm3 • RAL: +11/mm3 • No AIDS events • No difference in the overall incidence of adverse reactions between both groups • Higher incidence of grade 1 to 4 laboratory abnormalities in the RAL arm (p = 0.001) • Median increases in triglycerides and total cholesterol were significantly higher in the RAL group De Castro N, CID 2009;49:1259-67 EASIER

  5. EASIER Study: Switch ENF to RAL Grade 3 or 4 emerging adverse events or laboratory abnormalities De Castro N, CID 2009;49:1259-67 EASIER

  6. EASIER Study: Switch ENF to RAL • Conclusions from W24 data • In patients infected with multidrug-resistant HIV-1 receiving suppressive enfuvirtide-containing antiretroviral therapy, aswitch from enfuvirtide to RAL is: • Safe • Well-tolerated • And virologically non-inferior to the maintenance of ENF De Castro N, CID 2009;49:1259-67 EASIER

More Related